

of acute stroke treatment with Cerebrolysin®

Khasanova, D.R., Kalinin, M.N. Cerebrolysin[®] as an Early Add-on to Reperfusion Therapy: Risk of Hemorrhagic Transformation after Ischemic Stroke (CEREHETIS), a prospective, randomized, multicenter pilot study. BMC Neurol 23, 121 (2023).

- Significant reduction of hemorrhagic transformation
- Significant improvement of BBB integrity
- Significant reduction of infarct volume
- Significant improvement of imaging data

Now also clinically proven



Reconnecting Neurons. Empowering for Life.

Complications after stroke treatment

GOLDEN STANDARD = RECANALISATION THERAPY rtPA or thromectomy

BUT it leads to **hemorrhagic complications and** 60% of patients **does not show expected** clinical results



Increased safety of acute stroke treatment

Significant reduction of hemorrhagic transformation



Rate of hemorrhagic complications, PP Analysis, day 14

- Significantly lower rate of hemorrhagic transformation (HT) with Cerebrolysin[®]
- **Only 13,7%** with hemorrhagic complications in Cerebrolysin[®] group vs. 22,9% in control group
- Cerebrolysin[®] reduces risk of HT by -40%

Now also clinically proven



• Cerebroprotective and BBB* stabilizing activity clinically proven!

Now also clinically proven

Significant reduction of infarct volume



- Significant reduction of infarct volume in Cerebroylsin® group
- Increased infarct volume in the placebo group
- Cerebrolysin[®] patients benefit from a **better quality of life**

Imaging data confirm



- Affected side very close to contralateral side in Cerebrolysin® group
- Big difference in the placebo group

Better functional outcome

Improvement of Activities of daily living with Cerebrolysin®





Start with Cerebrolysin[®] directly after recanalization!

- The **risk of HT** is established to be the highest **on day 1 after stroke** onset, and it keeps being significant for the next 14 days
- Consequently, pharmacological prevention of HT should be started as early as possible and should be continued for at least 2 weeks

Daily dosage	Initiation of treatment	Treatment Duration
20 – 50 ml	As soon as possible Directly after recanalization	10 – 21 days

Cerebrolysin[®] as an Early Add-on to Reperfusion



Title:	Cerebrolysin® as an Early Add-on to Reperfusion Therapy: Risk of Hemorrha Transformation after Ischemic Stroke (CEREHETIS), a prospective, randomiz multicenter pilot study.
Patients:	341 patients (126 Cerebrolysin® group vs. 215 Control group)
Treatment:	30ml/day, 14 days
Author:	Khasanova, et al. 2023
Journal:	BMC Neurol 23, 121 (2023).
URL:	https://doi.org/10.1186/s12883-023-03159-w

Copyright © 2023 by EVER Neuro Pharma GmbH, Oberburgau 3, 4866 Unterach, Austria. All rights reserved. No part of this brochure may be reproduced in any form or by any electronic or mechanical means, including information storage and retrieval systems, without permission in writing from the publisher. Cerebrolysin® - solution for injection. Qualitative and guantitative composition: One ml contains 215.2 mg of Cerebrolysin® concentrate in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: For treatment of cerebrolysin® in the following indications: Senile dementia of Alzheimer's type. Vascular dementia. Stroke. Craniocerebral trauma (commotio and contusio). Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER Neuro Pharma GmbH, A+866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shell life, special precautions for storage, nature and contents of the container and special precautions for storage, nature waverpharma GmbH, available on the summary of product characteristics. (Reference SPC – CCDS Version 2.0/03.06.2016) EVER Neuro SPC – CCDS Version 2.0/03.06.2016) EVER Neuro Pharma GmbH, oww.weverpharma.com, www.cerepharma.com